Positive or close margins: reoperation rate and second conservative resection or total mastectomy?
breast cancer
conservative surgery
margins
mastectomy
reoperation
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
18
4
2019
pubmed:
18
4
2019
medline:
18
4
2019
Statut:
epublish
Résumé
Reoperation after breast-conserving surgery (BCS) could be proposed for positive or close margins. Reoperation type, re-excision or mastectomy, depends on several factors in relation to patient's and tumor's characteristics. We have analyzed our breast cancer (BC) database in order to determine second and third attempts for BCS and mastectomy rates, as well as associated factors for type of surgery. All patients with BCS between 1995 and 2017 were included. Patient's characteristics, pathologic results, and treatments were analyzed. Reoperation rate, type of reoperation, second reoperation, and associated factors of reoperation, mastectomy, and third intervention were determined. Three periods were determined: P1-P3. We analyzed 10,761 patients: 1,161 with ductal carcinoma in situ (DCIS) and 9,600 with invasive BC. The reoperation rate was 41.4% for DCIS and 28.0% for invasive BC. Using multivariate analysis, we identified tumor size >20 mm as being a risk factor for reoperation, whereas age >50 years, P2-3, and some localization decreased reoperation rates. For invasive BC, age >40 years, triple-negative tumors, neoadjuvant chemotherapy, and noncentral tumors decreased reoperation rates and lobular tumor, multifocal tumors, lymphovascular invasion, DCIS component, and Her2-positive tumors increased reoperation rates. For patients requiring reoperation, re-excision was performed in 48.1% (1,523/3,168) and mastectomy was required after first re-excision in 13.46% (205/1,523). For DCIS, mastectomy rates were higher for grade 2 and tumor ≥20 mm. For invasive BC, mastectomy rates were higher for lobular, multifocal, ≥20 mm, Her2-positive tumors and diffuse positive margins and lower for age >50 years and during the last period. Even if interval time between surgery and adjuvant treatments was higher for patients with reoperation, survival rates were not different between patients with and without reoperation. A decrease in reoperation and mastectomy rates had been reported with several associated factors. A third intervention with mastectomy was required in 13.5% of patients. This information should be done in case of reoperation.
Identifiants
pubmed: 30992681
doi: 10.2147/CMAR.S190852
pii: cmar-11-2507
pmc: PMC6445211
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2507-2516Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Ann Plast Surg. 2007 Sep;59(3):235-42
pubmed: 17721207
Ann Surg Oncol. 2009 Oct;16(10):2717-30
pubmed: 19609829
JAMA. 2009 Oct 14;302(14):1551-6
pubmed: 19826024
BMJ. 2012 Jul 12;345:e4505
pubmed: 22791786
Ann Surg Oncol. 2014 Oct;21(10):3185-91
pubmed: 25047472
JAMA Surg. 2014 Dec;149(12):1296-305
pubmed: 25390819
N Engl J Med. 2015 Aug 6;373(6):503-10
pubmed: 26028131
Anticancer Res. 2015 Jul;35(7):4229-34
pubmed: 26124383
Ann Surg. 2015 Oct;262(4):623-31
pubmed: 26366541
Ann Surg Oncol. 2016 Nov;23(12):3801-3810
pubmed: 27527714
Ann Surg Oncol. 2016 Dec;23(Suppl 5):656-664
pubmed: 27718033
JAMA Surg. 2017 Apr 1;152(4):378-384
pubmed: 28002557
Breast Cancer Res Treat. 2017 Jul;164(1):157-167
pubmed: 28389735
Ann Surg. 2018 Jul;268(1):165-171
pubmed: 28448389
Eur J Cancer. 2017 Oct;84:315-324
pubmed: 28865259
J Cancer. 2017 Aug 22;8(14):2653-2662
pubmed: 28928852
Am J Surg. 2017 Dec;214(6):1104-1109
pubmed: 28974314
BMC Health Serv Res. 2018 Feb 8;18(1):94
pubmed: 29422097
JAMA Oncol. 2018 May 1;4(5):747
pubmed: 29423506
BMJ Open. 2018 Apr 10;8(4):e020858
pubmed: 29643165
Eur J Surg Oncol. 2018 Jul;44(7):939-944
pubmed: 29705287
Ann Surg Oncol. 2018 Jul;25(7):1936-1942
pubmed: 29748884
ANZ J Surg. 2018 Sep;88(9):922-927
pubmed: 29763991